&w=3840&q=100)
This smallcap stock rallies 6% as board to consider fundraising on June 24
Astec LifeSciences share price: Chemical manufacturing company Astec LifeSciences shares zoomed up to 5.94 per cent to hit an intraday high of ₹784.65 per share on Friday, June 20, 2025.
By 11:40 AM, Astec LifeSciences shares were off day's high, but continued to trade 2.30 per cent higher at ₹757.70. In comparison, BSE Sensex was up 0.88 per cent at 82,081.23 levels. Catch Stock Market LIVE Updates Today
Why did Astec LifeSciences share price jump in trade today?
Astec LifeSciences shares rose after the company announced that its board will meet on June 24 to consider the proposal of fund raising via equity shares or any other securities through appropriate mode including rights issue.
In an exchange filing, Astec LifeSciences said, 'This is to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, June 24, 2025 to consider, inter alia, the proposal of fund raising by way of Equity Shares or any other securities through appropriate mode including rights issue, as may be permitted under applicable law and as may be decided by the Board, subject to such regulatory/statutory approvals as may be required.'
Astec LifeSciences Q4 results
Astec LifeSciences reported a consolidated total income of ₹120.3 crore for Q4FY25, down from ₹155.8 crore in Q4FY24. On a sequential basis, total income rose 25.6 per cent compared to Q3FY25.
Consolidated Ebitda stood at ₹6.3 crore in Q4FY25, lower than ₹14.8 crore in the year-ago quarter. However, it marked an improvement over Q3FY25 levels.
N B Godrej, chairman, Astec LifeSciences Limited, said, 'In Q4FY25, Astec reported sequential improvement in performance. Ebitda for Q4FY25 at ₹6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to increase in volumes and prices in Enterprise business coupled with improved product mix in the CDMO business. We expect an uptick in the demand for Enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.' ALSO READ |
About Astec LifeSciences
Established in 1994, Astec LifeSciences (Astec) is engaged in the production of agrochemical active ingredients (technicals), bulk formulations, and intermediate products.
The company maintains a balanced sales mix between domestic and export markets, with exports spanning over 17 countries, including the United States, and regions such as Europe, West Asia, South-East Asia, Latin America, and Africa.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
6 hours ago
- Economic Times
A Tale of Yaay! and Hmm: Is India's growth story impressive, or disappointing — or a bit of both?
Purchasing power, stop running away! We're doing fine! India has become the world's 5th-largest economy, eclipsing former economic giants like Britain. In a matter of 1-2 years, it should be the 4th-largest, surpassing Japan. Post-pandemic economic growth is nothing to be scoffed at. India is the world's fastest-growing major economy. Over the past 3 years, a rather turbulent period for the world economy, India's GDP increased at nearly 8% definitely. Yet, is the rising euphoria on India's escalating economic ranking justified? Perhaps. But only after we acknowledge the statistical meaning of being among the world's top-ranked economies. India is the world most populous country. In per-capita terms, we are still ranked as low middle-income. In per-capita nominal GDP, India is 143rd in a ranking of 194 countries. Adjusting for purchasing power parity (PPP), it's at 125th - the rank going up a few notches, but not very much. Humbling, yes. But let's not minimise the importance of being among the top 5 economies in overall GDP. China is 69th in nominal per-capital GDP, and 72nd in PPP per-capita GDP. Yet, its influence on the world stage is not diminished by its per-capita income ranking. China's economic and strategic influence is next to none, other than the US', and sometimes even an example, while most nations have cowed into pleasing Donald Trump and accepted his trade deals, China has decided to fight - and appears to be winning. Many countries are weighing whether they should develop closer alliances with China or the US, and how the others will India's influence will also be measured by its overall ranking in GDP, and not just by its per-capita ranking. Yet, let's keep in view that gap between India and the top two world economies. The US economy is $30 tn in nominal GDP. The Chinese economy is $19 tn. India's is far, far below at $3.9 tn. Humbling, vs expectations: that's the other aspect of India's growth story. In 2018, GoI pledged that India would be a $5 tn economy by 2025. This was a target that many experts viewed with amused scepticism. Of course, progress was halted by the two years of the pandemic. But for those long waiting for the arrival of the $5 tn economy, it's still disappointing to see that we are just halfway towards the 2018-19, India's GDP was $2.8 tn. In 2024-25, it's still $1.1 tn short of the target. Now we hope to achieve that target by of leading sectors - where the world acknowledges India's influence - also brings a mixed tale of optimism and caution. India is the world's largest user of ChatGPT, and, according to a Microsoft, Bain & Company, and Internet and Mobile Association of India (IAMAI) report, home to 16% of the world's AI talent. Impressive, has the ambition to lead the world in AI and Narendra Modi says, 'AI will remain incomplete without India.' Yet, so far, India doesn't have an indigenous foundational language model, and it's 3-5 years away from developing domestic AI chips. It lags substantially behind other nations in attracting investment in by Stanford University researchers suggest that India received only $1.2 bn in private investment in AI. Of course, the US received the lion's share - $109 bn. But China received 7x than India. A recent article in The Economist asks whether India can be an AI winner. It cautiously concludes that it has a lot to do to lead the most-talked-about achievement on the manufacturing front is that Apple is now assembling 20% of its smartphones sold worldwide in India. By 2026, it is planning to assemble in India all smartphones it will sell in the US. Again, impressive. Yet, the humbling reality is that India is simply assembling the phones, with almost all of their parts being manufactured in China or Southeast Asia. Hopefully, this will change once Foxconn, Apple's top supplier, sets up production facilities in biggest propeller for future economic growth is investment in Rundefined the US 3.5% of its even-larger in sectors where India has emerged as a top global supplier, investment in R&D is pathetic. India often labels itself the 'pharmacy of the world'. Indian pharma supplies 20% of all generic drugs globally, and 40% of generic drugs used in the US. Generic drugs do not need R& the non-generic sector is substantially driven by R&D. According to the Journal of Medicinal Chemistry, in pharmaceuticals, China's R&D investment is 16x India's. India imports 70% of its drug ingredients from China. Clearly, in some sense, we are far behind China even in sectors where we have a major global presence. (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. How Vedanta's Anil Agarwal bettered Warren Buffett in returns Rivers are moving more goods than before. But why aren't they making a splash yet? Why Infy's Parekh takes home more than TCS' CEO despite being smaller Is India ready to hit the aspirational 8% growth mark? Aadit Palicha on Zepto dark store raid, dark patterns, and IPO Stock Radar: MCX rallies over 50% in just 3 months to hit fresh highs! What should investors do in June – buy or book profits? Metal stocks: Candidates for tactical and contrarian investing? 6 metal stocks with an upside potential of up to 39% Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus
&w=3840&q=100)
Business Standard
6 hours ago
- Business Standard
CAPE fear: History suggests rich valuations precede sharp pullbacks
Valuations at current levels have historically corresponded single-digit returns premium Sachin P Mampatta Mumbai Listen to This Article Notwithstanding indices being lower than the all-time high levels touched nine months ago, the stock market has rarely been as expensive as it is now on one particular metric. The 10-year cyclically adjusted price-to-earnings (CAPE) ratio for the BSE Sensex is at 35.2x, according to data based on a study, Forecast or Fallacy? Shiller's CAPE: Market and Style Factor Forward Returns in Indian Equities, authored originally in July 2024 by Joshy Jacob, professor at the Indian Institute of Management, Ahmedabad, and Rajan Raju, director at Singapore-based family office Invespar. The numbers are updated monthly. The latest valuations for May 2025
United News of India
7 hours ago
- United News of India
Sensex Zooms by 1,046.30 points
Mumbai, Jun 20 (UNI) Snapping three consecutive sessions of losses, the BSE Sensex on Friday surged by 1,0436 points to close at 82,408.17. Today's surge is seen as the result of gains in Asian markets and renewed foreign fund inflow, a trader explained. Markets sentiments turned bullish after the US President Donald Trump announced that he will decide in the next two weeks whether or not to get involved in the Iran-Israel conflict. This announcement eased crude oil prices improving investor sentiments, the trader added. National Stock Exchange (NSE) too advanced by 319.15 points to settle at 25,112.40. The Sensex opened marginally lower at 81,354,85 against its previous close of 81,361.87 .66 Sensex recorded an intra day high of 82,641.54 and low of 81,323.20. The NSE registered a day's high at 25,132.80 and a day's low at 24,738.10 Mid-cap rose by 1.20 pc and the Small-cap advanced by 0.22 pc. The market breadth stayed strong on Friday. The BSE witnessed 2,469 shares rising and 1,471 shares falling. A total of 151 shares remained unchanged. All Sectoral indices ended the Session in green with Telecom being the Top Sectoral gainer up by 2.73 pc Other Sectoral gainer were Commodities by 0.54 pc. Energy By 0.99 pc, FMCG by 0.52 pc, Financial by 1.35 pc, Health Care by 0.78 pc, Industrial by 1.21 pc, IT by 0.65 pc, Utilities by 1.62 pc, Auto by 0.84 pc, Bankex by 1.15 pc, Capital Goods by 1.17 pc, Consumer Durables by 0.84 pc, Metals by 1.10 pc, Oil & Gas bty 0.61 pc, Power by 1,46 pc , Realty by 2.22 pc and Teck by 1.42 pc Among the 30 scrips, 27 advanced while 3 declined. Notable gainers were Bharti Airtel by 3.17 pc to Rs 1,935.00, Nestle India by 2.98 pc to Rs 2,388.20, M&M by 2.86 pc to Rs 3,180.20, Power Grid by 2.18 pc to Rs 292.55, Reliance by 2.16 pc to Rs 1,462.65, NTPC by 1.70 to RS 33.35 and Eternal by 1.60 pc to Rs 253.40. The losers were Axis Bnak by 0.16 pc to Rs 1,215.00, Ultra tech by 0.07 pc to Rs 11,399.70 and Maruti by 0.02 pc to Rs 12,803.00. US Dow Jones futures were up by 0.56 pc, European shares advanced on Friday, FTSE by 0.47 pc, CAC by 0.58 pc and DAX by 0.95 pc Most Asian markets ended higher as investors assessed China data and monitored escalating tensions between Israel and Iran. Nikkei was 225 down by 0.22 pc, Straits Times rose by 0.28 pc, Hang Seng advanced by 1.24 pc and Kospi by 1.46 pc. UNI JS RKM
